Top

Published in:

01-01-2008 | Epidemiology

Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1

Authors: Cheng-Ping Yu, Jyh-Cherng Yu, Chien-An Sun, Ching Tzao, Jar-Yi Ho, Amy Ming-Fang Yen

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

We aimed to investigate the role of CCND1 G870A polymorphism genetic and transcriptomic effects susceptibility in association with breast cancer carcinogenesis and clinical prognosis. A case-control study was conducted with the enrollment of 992 sporadic breast cancer patients and the corresponding 960 normal controls from routine mammographic or sonographic screening for breast cancer between 1995 and 2003 in Taiwan. The 167 fragment spanning the G870A polymorphism in exon 4-intron 4 boundary was amplified to identify genotype of CCND1 (G870A) polymorphism. Competitive RT-PCR were further performed to investigate alternative transcript in four different specimens in association with immunohistochemistry markers. The results showed that AG and AA subgroup were at increased risk for developing breast cancer compared with the GG genotype by 19% (OR 1.19 (0.85–1.67)) and by 34% (OR 1.34 (0.04–1.74)), respectively. A870 allele revealed a recessive tendency while GG and AA/AG subgroup was compared (OR 1.35 (1.07–1.70)). AA genotype also had a higher risk in premenopausal women than postmenopausal ones. The recurrence-free survival was longer in patients with GG+AG than that in patients with AA (P = 0.034). A870 allele produced more transcript b both in malignant. There were significant correlations between several immunohistochemistry markers (such as Ki-67) and cyclin D1 or CDk4. We concluded CCND1 G870A polymorphism make significant contribution to breast cancer in the country with the preponderance of breast cancer in young women. The role of G870A polymorphism in alternative transcript was not only implicated in CCND1 alternative splicing but also correlated with immunohistochemistry markers.

Motokura T, Bloom T, Kim HG et al (1991) A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512–515PubMedCrossRef

Rosenberg CL, Wong E, Petty EM et al (1991) PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Nat Acad Sci USA 88:9638–9642PubMedCrossRef

Komatsu H, Iida S, Yamamoto K et al (1994) A variant chromosome translocation at 11q13 identifying PRAD1/ cyclin D1 as the BCL-1gene. Blood 84:1226–1231PubMed

Withers DA, Harvey RC, Faust JB et al (1991) Characterization of a candidate bcl-1 gene. Mol Cell Biol 11:4846–4853PubMed

Sherr CJ (1995) D type cyclins. Trends Biochem Sci 20:187–190PubMedCrossRef

Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677PubMedCrossRef

Kandel R, Zhu XL, Li SQ et al (2001) Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk. Eur J Cancer Prev 10:43–51PubMedCrossRef

Bartkova J, Lukas J, Muller H et al (1994) Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353–361PubMedCrossRef

Courjal F, Louason G, Speiser P (1996) Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247–253PubMedCrossRef

10.

Zhou Q, Hopp T, Fuqua SA et al (2001) Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett 162:3–17PubMedCrossRef

11.

Gillett C, Smith P, Gregory W et al (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92–99PubMedCrossRef

12.

Hosokawa Y, Tu T, Tahara H et al (1995) Absent of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett 93:165–170PubMedCrossRef

13.

Knudsen KE, Diehl JA, Haiman CA et al (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25:1620–1628PubMedCrossRef

14.

Knudsen KE (2006) The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div 1(15)

15.

Gillett C, Fantl V, Smith R et al (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812–1817PubMed

16.

Bieche I, Olivi M, Nogues C et al (2002) Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86:580–586PubMedCrossRef

17.

Terry MB, Gammon MD, Schoenberg JB et al (2002) Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 11:1100–1103PubMed

18.

Barnes DM, Gillett CE (1998) Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1–15PubMedCrossRef

19.

Betticher DC, Thatcher N, Altermatt HJ et al (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005–1011PubMed

20.

Sawa H, Ohshima TA, Ukita H et al (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16:1701–1712PubMedCrossRef

21.

Alt JR, Cleveland JL, Hannink M et al (2000) Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102–3114PubMedCrossRef

22.

Solomon DA, Wang Y, Fox SR et al (2003) Cyclin D1 spliced variants: differential effects on localization, Rb phosphorylation, and cellular transformation. J Biol Chem 278:30339–30347PubMedCrossRef

23.

Lu F, Gladden AB, Diehl JA (2003) An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63:7056–7061PubMed

24.

Burd CJ, Petre CE, Morey LM et al (2006) Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 103:2190–2195PubMedCrossRef

25.

Carrere N, Belaud-Rotureau MA, Dubus P et al (2005) The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica 90:854–586PubMed

26.

Hershenson MB (2004) p21Waf1/Cip1 and the prevention of oxidative stress. Am J Physiol Lung Cell Mol Physiol 286:L502–L505PubMedCrossRef

27.

Loo G (2003) Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). J Nutr Biochem 14:64–73PubMedCrossRef

28.

Brown NS, Bicknell R (2001) Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3:323–327PubMedCrossRef

29.

Ceschi M, Sun CL, Van Den Berg D et al (2005) The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26:1457–1464PubMedCrossRef

30.

Howe D, Lynas C (2001) The cyclin D1 alternative transcripts (a) and (b) are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86:563–569PubMed

31.

Shu XO, Moore DB, Cai Q et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14:91–97PubMed

32.

Krippl P, Langsenlehner U, Renner W et al (2003) The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82:165–168PubMedCrossRef

33.

Grieu F, Malaney S, Ward R et al (2003) Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23:4257–4259PubMed

34.

Wang L, Habuchi T, Takahashi T et al (2002) Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257–264PubMedCrossRef

35.

Gladden AB, Woolery R, Aggarwal P et al (2006) Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25:998–1007PubMedCrossRef

36.

Barnes DM, Gillett CE (1998) Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1–15PubMedCrossRef

37.

Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571PubMedCrossRef

38.

Smith PJ, Zhang C, Wang J et al (2006) An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 15:2490–2508PubMedCrossRef

39.

Palmero I, Peters G (1996) Perturbation of cell cycle regulators in human cancer. Cancer Surv 27:351–367PubMed

40.

Matsushime H, Ewen ME, Strom DK et al (1992) Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323–334PubMedCrossRef

41.

Kato J, Matsushime H, Hiebert SW et al (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331–342PubMedCrossRef

42.

Ewen ME, Sluss HK, Sherr CJ et al (1993) Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487–497PubMedCrossRef

43.

Liu F, Matsuura I (2005) Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 4:63–66PubMed

44.

Canhoto AJ, Chestukhin A, Litovchick L et al (2000) Phosphorylation of the retinoblastoma-related protein p130 in growth-arrested cells. Oncogene 19:5116–5122PubMedCrossRef

Title: Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1
Authors: Cheng-Ping Yu
Jyh-Cherng Yu
Chien-An Sun
Ching Tzao
Jar-Yi Ho
Amy Ming-Fang Yen
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9522-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Screening for ATM sequence alterations in African-American women diagnosed with breast cancer

Intake of fruits, and vegetables in relation to breast cancer risk by hormone receptor status

BARD1 and breast cancer in Poland

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen

Dietary animal-derived iron and fat intake and breast cancer risk in the Shanghai Breast Cancer Study

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer